title: Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?
abstract: The childhood forms of polycystic kidney disease are autosomal recessive polycystic kidney disease and nephronophthisis. In animal models of these diseases, characterised by a defect in urine concentration progressing to renal failure, the selective vasopressin receptor type 2 antagonist OPC-31260 halted the progression or even caused regression of the established disease. Vasopressin receptor type 2 antagonists should proceed to clinical trial for these polycystic kidney diseases.
authors.affiliation: Doggrell Biomedical Communications, Auckland, New Zealand. s_doggrell@yahoo.com
authors.forename: Sheila A
authors.initials: SA
authors.lastname: Doggrell
mesh_terms: D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007690:Polycystic Kidney Diseases / Q000188:drug therapy*
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; C076251:mozavaptan